Literature DB >> 17942577

Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36).

Takehisa Onishi1, Kouhei Nishikawa, Yoshihiro Hasegawa, Yasushi Yamada, Norihito Soga, Kiminobu Arima, Koichiro Yamakado, Akira Hoshina, Yoshiki Sugimura.   

Abstract

OBJECTIVE: The purpose of this study was to assess the changes in health-related quality of life (HRQoL) during follow-up period in patients treated with percutaneous radiofrequency ablation (RFA) or laparoscopic surgery for small renal cell carcinoma.
METHODS: From December 2004 through September 2006, for 37 consecutive patients, who were diagnosed with renal cell carcinoma and underwent percutaneous RFA (n = 20) or laparoscopic radical nephrectomy (n = 17) at our institution. HRQoL was evaluated prospectively using SF-36 Health survey pre- and post-operatively (1, 4, 12 and 24 weeks after surgery).
RESULTS: Four of the eight scale scores of SF-36 were significantly lower pre-operatively in the RFA group than in the laparoscopic surgery group. The QoL scores in physical functioning, role-physical functioning and role-emotional functioning were significantly reduced one week after laparoscopic surgery. However, there was no reduction of the SF-36 QoL scores one week after operation in the RFA group. Furthermore, HRQoL scores in the RFA group showed a tendency to improve during follow-up periods.
CONCLUSIONS: This is the first study to evaluate HRQoL changes (up to 24 weeks) in patients who have undergone RFA or laparoscopic radical nephrectomy for small renal cell carcinoma. No reduction, but rather an improvement, in HRQoL was seen in the RFA group during follow-up periods. From the point of view of QoL, RFA could be a viable alternative treatment for selected patients with small renal cell carcinoma. RFA could be a viable alternative treatment for the selected patients with small renal cell carcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17942577     DOI: 10.1093/jjco/hym107

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Percutaneous radiofrequency ablation for treatment of giant cell tumor of bone guided by real-time US fused with CT.

Authors:  Qiyu Zhao; Lifeng Wang; Fen Chen; Tian-An Jiang
Journal:  J Med Ultrason (2001)       Date:  2013-07-24       Impact factor: 1.314

2.  Evaluation of patient-reported quality-of-life outcomes after renal surgery.

Authors:  Sarah B Kim; Stephen B Williams; Su-Chun Cheng; Martin G Sanda; Andrew A Wagner
Journal:  Urology       Date:  2012-04-28       Impact factor: 2.649

3.  Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Peter R Mueller; Chin Hur; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

Review 4.  Common uses and cited complications of energy in surgery.

Authors:  Ganesh Sankaranarayanan; Rajeswara R Resapu; Daniel B Jones; Steven Schwaitzberg; Suvranu De
Journal:  Surg Endosc       Date:  2013-04-23       Impact factor: 4.584

5.  The 36-item short form health survey: reliability and validity in Chinese medical students.

Authors:  Yang Zhang; Bo Qu; Shi-Si Lun; Ying Guo; Jie Liu
Journal:  Int J Med Sci       Date:  2012-08-27       Impact factor: 3.738

6.  Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1-a systematic review.

Authors:  Theresa Junker; Louise Duus; Benjamin S B Rasmussen; Nessn Azawi; Lars Lund; Ole Graumann; Birgitte Nørgaard
Journal:  Syst Rev       Date:  2022-01-04

7.  Comparison of baseline quality of life measures between renal cell carcinoma patients undergoing partial versus radical nephrectomy.

Authors:  Michelle L Arnold; David D Thiel; Nancy Diehl; Kevin J Wu; Steve Ames; Alexander S Parker
Journal:  BMC Urol       Date:  2013-10-22       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.